-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, it is the 2021 annual report disclosure period of listed companies, and the profitability of major companies has attracted much attention in the industry
.
According to data from Flush, as of April 27, among the listed companies in the pharmaceutical and biological industry that have disclosed their annual reports, a total of 44 will achieve revenue of over 10 billion yuan in 2021
.
From the point of view of gross profit margin, the core indicator for measuring corporate profitability, among these 44 pharmaceutical companies, 3 have gross profit margin of over 80%, namely Changchun Hi-Tech (87.
61%), Hengrui Medicine (85.
61%), Zhongsheng Pharmaceutical (80.
2%); in addition, there are 13 companies whose sales gross profit margin exceeds 50%
.
According to the industry, gross profit margin refers to the percentage of gross profit in sales or revenue.
If the gross profit margin is high, it means it is a good business, and the factors that affect the gross profit margin of sales include the competition pattern of the market, the marketing strategy of the company, and the research and development invested by the company.
costs and fixed asset costs
.
So in the context of high gross profit margins, how much net profit did these pharmaceutical companies get? Judging from the three pharmaceutical companies with a gross profit margin of over 80%, Changchun Hi-Tech will achieve a net profit of 610 million yuan in 2021, a year-on-year decrease of 22.
4%
.
Compared with the same period in 2020, the growth rate of Changchun Hi-Tech's net profit has slowed down significantly
.
It is worth mentioning that the recombinant human growth hormone production company Jinsai Pharmaceutical is the profit pillar of Changchun Hi-Tech.
This subsidiary will achieve a net profit of 3.
684 billion yuan in 2021, accounting for about 98% of Changchun Hi-Tech's current net profit attributable to its parent.
.
According to the 2021 annual report of Hengrui Medicine, the net profit attributable to shareholders of listed companies for the year was about 4.
53 billion yuan, a year-on-year decrease of 28.
41%
.
The company said that due to the company's accelerated R&D investment, centralized procurement with volume, and the substantial price reduction of national medical insurance negotiated products, the gross profit margin has declined, the cost of raw and auxiliary materials and other costs continued to rise, and the combined impact of high operating and personnel costs in early 2021 the company's performance
.
It is reported that in 2021, Hengrui Medicine's R&D investment will reach a new high of 6.
203 billion yuan, an increase of 24.
34% over the previous year, and R&D investment will account for 23.
95% of sales revenue
.
Zhongsheng Pharmaceutical will achieve a net profit of 14.
61 billion yuan in 2021, a year-on-year increase of 427.
2%
.
It is reported that the company's good performance is mainly due to the strong growth of new products on the market within five years.
Among them, the three major business sectors of anti-tumor, cardiovascular and cerebrovascular, and respiratory have grown strongly.
The revenue of anti-tumor products was 9.
22 billion yuan, a year-on-year increase of 21%
.
The blockbuster products of Anlotinib and Piamprimab have made a concerted effort to become a super-strong tumor combination backbone therapy
.
By the end of 2021, Zhongsheng Pharmaceutical has sold 50 products with sales of over 100 million yuan, including 6 products with sales of over 1 billion yuan, and 8 products with sales of 500 million yuan to 1 billion yuan
.
In 2021, the company has obtained as many as 36 product registration approvals
.
In terms of the year-on-year change in gross profit margin, 21 of the 44 companies achieved a year-on-year increase in gross profit margin.
Among them, Baiyunshan ranked first, with a gross profit margin of 19.
17% in 2021, a year-on-year increase of 2.
25 percentage points
.
Followed by, Taiji Group, Zhongsheng Pharmaceutical, the gross profit margin of sales increased by 2.
08 percentage points and 2.
06 percentage points respectively year-on-year
.
Of course, there are joys and sorrows.
Affected by factors such as centralized procurement and product price reduction under medical insurance negotiations, as well as market competition and rising costs, the gross profit margin of some pharmaceutical companies has declined, such as Xinhecheng and Fosun Pharma
.
Fosun Pharma's 2021 annual report shows that the gross profit margin of the company's pharmaceutical business decreased by 8.
27 percentage points year-on-year.
Among them, the gross profit margin of anti-tumor and immunomodulatory core products decreased by 0.
6 percentage points year-on-year, mainly due to the implementation of avatrombopag maleate tablets.
The sales unit price decreased after the negotiated price of medical insurance; the gross profit margin of the core products of metabolism and digestive system decreased by 5.
9 percentage points compared with the same period, mainly due to the decrease in the sales unit price of febuxostat tablets after the centralized procurement
.
The analysis pointed out that under the normalization of centralized procurement and medical insurance, drug prices have become a trend, and pharmaceutical companies are facing challenges in controlling costs and other aspects
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to data from Flush, as of April 27, among the listed companies in the pharmaceutical and biological industry that have disclosed their annual reports, a total of 44 will achieve revenue of over 10 billion yuan in 2021
.
From the point of view of gross profit margin, the core indicator for measuring corporate profitability, among these 44 pharmaceutical companies, 3 have gross profit margin of over 80%, namely Changchun Hi-Tech (87.
61%), Hengrui Medicine (85.
61%), Zhongsheng Pharmaceutical (80.
2%); in addition, there are 13 companies whose sales gross profit margin exceeds 50%
.
According to the industry, gross profit margin refers to the percentage of gross profit in sales or revenue.
If the gross profit margin is high, it means it is a good business, and the factors that affect the gross profit margin of sales include the competition pattern of the market, the marketing strategy of the company, and the research and development invested by the company.
costs and fixed asset costs
.
So in the context of high gross profit margins, how much net profit did these pharmaceutical companies get? Judging from the three pharmaceutical companies with a gross profit margin of over 80%, Changchun Hi-Tech will achieve a net profit of 610 million yuan in 2021, a year-on-year decrease of 22.
4%
.
Compared with the same period in 2020, the growth rate of Changchun Hi-Tech's net profit has slowed down significantly
.
It is worth mentioning that the recombinant human growth hormone production company Jinsai Pharmaceutical is the profit pillar of Changchun Hi-Tech.
This subsidiary will achieve a net profit of 3.
684 billion yuan in 2021, accounting for about 98% of Changchun Hi-Tech's current net profit attributable to its parent.
.
According to the 2021 annual report of Hengrui Medicine, the net profit attributable to shareholders of listed companies for the year was about 4.
53 billion yuan, a year-on-year decrease of 28.
41%
.
The company said that due to the company's accelerated R&D investment, centralized procurement with volume, and the substantial price reduction of national medical insurance negotiated products, the gross profit margin has declined, the cost of raw and auxiliary materials and other costs continued to rise, and the combined impact of high operating and personnel costs in early 2021 the company's performance
.
It is reported that in 2021, Hengrui Medicine's R&D investment will reach a new high of 6.
203 billion yuan, an increase of 24.
34% over the previous year, and R&D investment will account for 23.
95% of sales revenue
.
Zhongsheng Pharmaceutical will achieve a net profit of 14.
61 billion yuan in 2021, a year-on-year increase of 427.
2%
.
It is reported that the company's good performance is mainly due to the strong growth of new products on the market within five years.
Among them, the three major business sectors of anti-tumor, cardiovascular and cerebrovascular, and respiratory have grown strongly.
The revenue of anti-tumor products was 9.
22 billion yuan, a year-on-year increase of 21%
.
The blockbuster products of Anlotinib and Piamprimab have made a concerted effort to become a super-strong tumor combination backbone therapy
.
By the end of 2021, Zhongsheng Pharmaceutical has sold 50 products with sales of over 100 million yuan, including 6 products with sales of over 1 billion yuan, and 8 products with sales of 500 million yuan to 1 billion yuan
.
In 2021, the company has obtained as many as 36 product registration approvals
.
In terms of the year-on-year change in gross profit margin, 21 of the 44 companies achieved a year-on-year increase in gross profit margin.
Among them, Baiyunshan ranked first, with a gross profit margin of 19.
17% in 2021, a year-on-year increase of 2.
25 percentage points
.
Followed by, Taiji Group, Zhongsheng Pharmaceutical, the gross profit margin of sales increased by 2.
08 percentage points and 2.
06 percentage points respectively year-on-year
.
Of course, there are joys and sorrows.
Affected by factors such as centralized procurement and product price reduction under medical insurance negotiations, as well as market competition and rising costs, the gross profit margin of some pharmaceutical companies has declined, such as Xinhecheng and Fosun Pharma
.
Fosun Pharma's 2021 annual report shows that the gross profit margin of the company's pharmaceutical business decreased by 8.
27 percentage points year-on-year.
Among them, the gross profit margin of anti-tumor and immunomodulatory core products decreased by 0.
6 percentage points year-on-year, mainly due to the implementation of avatrombopag maleate tablets.
The sales unit price decreased after the negotiated price of medical insurance; the gross profit margin of the core products of metabolism and digestive system decreased by 5.
9 percentage points compared with the same period, mainly due to the decrease in the sales unit price of febuxostat tablets after the centralized procurement
.
The analysis pointed out that under the normalization of centralized procurement and medical insurance, drug prices have become a trend, and pharmaceutical companies are facing challenges in controlling costs and other aspects
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
